Nevertheless, PD-1+TIM-3+ T cells persist in the tumor microenvironment (TME), and even dominate the tumor-infiltrating CD8 T cell pool in some cancer types; their presence is associated with tumor reactivity and predicts response to PD-1 blockade in cancer patients23–26. This evidence concerns the gene HAVCR2 and cancer.